ClinicalTrials.gg
CompletedNCT06994936Updated Dec 9, 2025

An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector

A Phase 1 interventional study of Sonelokimab and Sonelokimab in Relative Bioequivalence, sponsored by MoonLake Immunotherapeutics AG. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-09.

Sponsored by MoonLake Immunotherapeutics AG · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a study to confirm the relative bioequivalence of sonelokimab administered subcutaneously via a prefilled syringe (PFS) or an autoinjector (AI) in healthy adult volunteers

02

Conditions studied

  • Relative Bioequivalence
03

In context

Lead sponsor

MoonLake Immunotherapeutics AG is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be between 18 and 55 years of age with suitable veins for cannulation or repeated venipuncture .
  • Participants must have a body weight greater than 40 kg and (BMI) between 21 and 30 kg/m2, inclusive.
  • Participants who are overtly healthy as determined by medical evaluation including medical history, physician examination, laboratory tests, and cardiac monitoring.
  • Female participants are eligible to participate if they are not pregnant or breastfeeding
  • Male participants must be willing to use a condom when sexually active with a partner of during the study, unless surgically sterile.

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.
  • History of clinically significant infections.
  • Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric.
  • History of , intolerance, or severe adverse reaction to any drug compound, any history of anaphylaxis or angioedema, or any history of severe food allergy/intolerance requiring systemic treatment.
  • Participants with transaminase and liver function test results outside of the normal reference range, following a confirmatory test, if appropriate
  • Participants with other clinically significant laboratory test results that are likely to introduce additional risk factors or interfere with the study procedures or interpretation.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Sonelokimab via a PFS

    Drug: Sonelokimab

  • Experimental
    Sonelokimab via an AI

    Drug: Sonelokimab

Interventions

  • sonelokimab 120 mg administered subcutaneously via a PFS

  • sonelokimab 120 mg administered subcutaneously via an AI

06

What researchers measure

Primary outcomes

  1. Comparison of pharmacokinetics (PK) of an AI versus PFS administered single dose of sonelokimab

    To compare the PK of an AI versus PFS administered single-dose of sonelokimab in terms of maximum concentration (Cmax)

    Time frame: 64 days

  2. Comparison of pharmacokinetics (PK) of an AI versus PFS administered single dose of sonelokimab

    To compare the PK of an AI versus PFS administered single-dose of sonelokimab in terms of area under the time concentration curve to infinite time (AUC0-inf)

    Time frame: 64 days

  3. Comparison of pharmacokinetics (PK) of an AI versus PFS administered single dose of sonelokimab

    To compare the PK of an AI versus PFS administered single-dose of sonelokimab in terms of area under the time concentration curve from time zero to timepoint with last measurable concentration (AUC0-t)

    Time frame: 64 days

Secondary outcomes

  1. Assessment of safety and tolerability

    To assess the safety and tolerability of AI and PFS administered sonelokimab by treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events of special interest (AESIs)

    Time frame: 64 days

  2. Evaluation of the impact of injection site location on PK

    Evaluation of the impact of injection site location on PK by capturing the relative bioavailability (F%) for thigh injection of sonelokimab compared to abdomen

    Time frame: 64 days

  3. Evaluation of the impact of injection site location on PK

    Evaluation of the impact of injection site location on PK by capturing the relative bioavailability (F%) for upper-arm injection of sonelokimab compared to abdomen

    Time frame: 64 days

  4. Evaluation of the impact of injection site location on PK

    Evaluation of the impact of injection site location on PK by capturing the relative bioavailability (F%) for thigh injection of sonelokimab compared to upper arm

    Time frame: 64 days

  5. Immunogenicity of sonelokimab

    Description of the prevalence of antidrug antibodies (ADAs)

    Time frame: 64 days

07

Study locations

1 site
  • Clinical Site
    London, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2025 to primary completion in Nov 2025, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2025
First posted
May 29, 2025
StartActual
Jun 5, 2025
Primary completionActual
Nov 1, 2025
CompletionActual
Nov 1, 2025
Last update
Dec 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06994936
Lead sponsor
MoonLake Immunotherapeutics AG
Responsible party
Sponsor
First posted
May 29, 2025
Start date
Jun 5, 2025
Primary completion
Nov 1, 2025
Completion
Nov 1, 2025
Last update
Dec 9, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sonelokimab

Start the discussion